VAERS reports by lot

Janssen (J&J) COVID-19 lot 1855190: VAERS reports

215 VAERS reports list lot 1855190 as a Janssen (J&J) COVID-19 vaccine, received between 2021-12-24 and 2024-10-06. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
215
Reports
10%
Marked serious
4
With a death outcome
19
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological19627%
General / Systemic (non-local)15321%
Cardiac / Cardiovascular11115%
Gastrointestinal547%
Dermatological (non-injection-site)547%
Respiratory507%
Musculoskeletal375%
Injection-site / Local reaction233%
Allergic / Anaphylactic203%
Psychiatric / Neuropsychiatric162%
Autoimmune / Immune-mediated101%
Thrombotic / Hematological71%
Reproductive / Menstrual30%

Where reports came from

U.S. state of the reporter, where given (top 12).

California24
Florida18
New York14
New Jersey14
Pennsylvania13
Texas13
Massachusetts10
Michigan7
Maryland6
North Carolina6
Minnesota5
Georgia5

Reports by month received

2021-122
2022-0116
2022-0222
2022-0327
2022-0433
2022-0534
2022-0626
2022-0712
2022-0810
2022-0912
2022-101
2022-115
2022-125
2023-013
2023-041
2023-081
2023-112
2024-061
2024-102

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.